Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160021/S052

GORE VIABAHN VBX Balloon Expandable Endoprosthesis

W. L. Gore & Associates, Inc. · Decision date Jun 16, 2026

FDA DECISIONP160021/S052

What did the FDA decide?

FDA records P160021/S052 as a supplement to PMA P160021, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 16, 2026.

FDA approval order statement

approval of an updated controller within the stent crimper system
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 16, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160021/S052
Regulatory pathway
PMA supplement
Product code
PRL
Decision code
OK30
Decision date
Jun 16, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Iliac covered stent, arterial.

Product code
PRL
FDA device class
3

For the original device and its historical approval scope, see PMA P160021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160021 · Original PMA

    GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS

  2. P160021/S049 · Related supplement

    GORE VIABAHN VBX Balloon Expandable Endoprosthesis

  3. P160021/S048 · Related supplement

    GORE VIABAHN VBX Balloon Expandable Endoprosthesis

  4. P160021/S050 · Related supplement

    GORE VIABAHN VBX Balloon Expandable Endoprosthesis

  5. P160021/S052 received

    Application receipt date recorded by FDA.

  6. P160021/S052 · FDA decision

    30-Day Notice

  7. P160021/S051 · Related supplement

    GORE VIABAHN VBX Balloon Expandable Endoprosthesis

Timeline entries are records held by MedtechLedger for P160021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160021

Explore the linked device profile

Other records with product code PRL

Product / regulatory recordCompanyPathwayDecision dateSource
Atrium Medical Corp.PMA supplementMay 13, 2026FDA
Atrium Medical Corp.PMA supplementDec 22, 2025FDA
Bard Peripheral Vascular, Inc.PMA supplementSep 29, 2025FDA
Atrium Medical Corp.PMA supplementSep 12, 2025FDA
Atrium Medical Corp.PMA supplementAug 20, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3250 W. Kiltie Ln., Flagstaff, AZ, 86005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records